*Staphylococcus aureus* is a leading cause of bacteremia, infective endocarditis, and device-related infection \[[@CIT0001]\]. Mortality rates for *S. aureus* bacteremia range from 10% to 50%, influenced in part by site of infection and choice of treatment \[[@CIT0002], [@CIT0003]\]. While vancomycin remains the preferred therapy for methicillin-resistant *S. aureus* (MRSA), beta-lactams are strongly associated with superior outcomes in methicillin-sensitive *S. aureus* (MSSA) bacteremia \[[@CIT0004]\].

Up to 10% of inpatients report beta-lactam allergies, frequently limiting appropriate treatment options for MSSA bacteremia \[[@CIT0005], [@CIT0006]\]. While prior studies have evaluated the treatment of patients with a reported penicillin allergy and outcomes of various antibiotic regimens, to our knowledge none have examined the influence of a reported penicillin allergy on MSSA bacteremia outcomes directly. We hypothesized that reported penicillin allergy might adversely impact survival in MSSA bacteremia by influencing treatment. Therefore, we performed this retrospective cohort study to quantify the effect of reported penicillin allergy on relevant clinical outcomes in adults with MSSA bacteremia.

METHODS {#s5}
=======

We retrospectively identified all adults with MSSA bacteremia admitted to Duke University Hospital (Durham, NC) from January 1, 2010, to December 31, 2015. MSSA bacteremia was defined as 1 or more blood cultures positive for *S. aureus* that was susceptible to oxacillin per Clinical Laboratory and Standards Institute guidelines (minimum inhibitory concentration ≤ 2 µg/mL). We excluded patients with polymicrobial bacteremia, those who died before final culture and susceptibility results were available, and those who elected not to pursue treatment (eg, pursued hospice care or left against medical advice). Our study was approved by the Institutional Review Board of the Duke University Health System.

Data collected retrospectively included each patient's demographic characteristics, sequential organ failure assessment (SOFA) score on the first day positive blood cultures were obtained, comorbid conditions, Charlson comorbidity index, reported drug allergies as of the day of admission, antibiotics received, duration of therapy, and serum vancomycin trough concentrations when available. Reported drug allergies were obtained directly from the electronic medical record, as recorded by the admitting physician, along with a description of the drug reaction when available. The source of infection was recorded from either an infectious disease consult note or the relevant discharge summary. Of note, our hospital implemented a policy for mandatory infectious diseases consultation for *S. aureus* bacteremia during the latter half of the study period, 2013--2016.

We analyzed 2 factors for association with clinical outcomes. Reported penicillin allergy was obtained from each patient's list of drug allergies documented within their admission history and physical. Definitive antibiotic choice was defined as the antibiotic prescribed once susceptibility results were known. Patients who expired before antibiotic susceptibility results were available were excluded from analysis. This was done to minimize the risk of bias toward worse outcomes with vancomycin given that nearly all patients received vancomycin as part of initial empiric therapy. Sensitivity analysis showed no significant effect upon including or excluding these patients (data not shown).

The primary end points included death at 30 days and death at 90 days. Secondary outcomes included time to clearance of blood cultures (defined as the number of days from first positive to first confirmed negative blood cultures), recurrence of bacteremia by 90 days, and incidence of adverse drug events. We used standard descriptive statistics. Comparisons between categorical variables were conducted using either the Fisher exact or χ^2^ where appropriate. Comparisons between continuous variables were conducted using *t* tests. All tests were 2-sided; *P* values were considered significant if \<.05. Outcomes of interest were examined first according to reported penicillin allergy, as this was our primary question. We next analyzed the data according to treatment choice as we hypothesized that reported penicillin allergy might influence outcomes indirectly by altering treatment choice.

Mortality outcomes were also evaluated using multivariable logistic regression. We constructed a stepwise regression model to adjust for confounders. All variables with *P* \< .2 were included initially, with backwards elimination to remove confounders with a \<10% effect on mortality. We did not include receipt of a beta-lactam in the multivariate model estimating the effect of reported penicillin allergy, as we considered this factor a potential mediator of the effect of penicillin allergy on mortality. We used the statistical platform R version 3.4.1 (available at <https://www.r-project.org/>) for all analyses.

RESULTS {#s6}
=======

Six hundred eighty-seven patients had *S. aureus* bacteremia during the study period. Exclusion of those with methicillin-resistant *Staphylococcus aureus* (MRSA) infection, polymicrobial infection, or those choosing not to pursue treatment left 335 patients. Of these 335 patients with MSSA bacteremia, 17 expired before susceptibility results were known and before definitive therapy could be chosen. These 17 were excluded from analysis, leaving 318 subjects with MSSA bacteremia in our final cohort. The majority of patients were male (n = 203, 64%), and the mean age was 58 (±16) years. The majority of patients received a beta-lactam antibiotic (n = 243, 76%). A large number of patients reported a penicillin allergy (n = 66, 21%). Among patients reporting penicillin allergy, the most common reactions reported were rash (n = 19, 27%) and hives (n = 15, 21%). A complete description of the reaction was not available for 15 (21%) cases. Reported penicillin reactions are summarized in [Table 1](#T1){ref-type="table"}. Twenty-nine (44%) reportedly penicillin-allergic patients still received cefazolin. Adverse drug events were too infrequent for analysis. Only a single incidence of suspected drug rash was noted in a patient with reported penicillin allergy who received a beta-lactam, along with 2 episodes of acute renal injury attributed to antibiotics. No episodes of anaphylaxis were noted.

###### 

Reported Reactions to Penicillin

  Reported Reaction to Penicillin   No. (%)
  --------------------------------- ---------
   Rash                             19 (27)
   Hives                            15 (21)
   Swelling/angioedema              8 (11)
   Anaphylaxis                      5 (7)
   Interstitial nephritis           5 (7)
   Dyspnea                          3 (4)
   Gastro-intestinal upset          1 (1)
   Unspecified                      15 (21)

The group with reported penicillin allergy was different than the nonallergic group by sex and some comorbidities ([Table 2](#T2){ref-type="table"}), but the 2 groups were similar in terms of overall Charlson comorbidity index and sequential organ failure assessment (SOFA) scores. There was a trend toward higher frequency of catheter infections in non-penicillin-allergic patients and a higher frequency of endovascular or soft tissue infection in penicillin-allergic patients ([Table 3](#T3){ref-type="table"}), though only the latter 2 reached statistical significance. Mortality rates were not significantly different between penicillin-allergic and non-penicillin-allergic patients at 30 days (10.6% vs 11.9%, *P* = .99) or 90 days (13.6% vs 18.3%, *P* = .47) in univariate analysis. Penicillin-allergic patients were slower to clear blood cultures (6.2 days vs 4.1 days, *P* \< .01) and more likely to suffer recurrence within 90 days (7% vs 1.5%, *P* = .02).

###### 

Demographics and Comorbidities for 318 Patients With MSSA Bacteremia According to Penicillin Allergy

  Characteristics                         Allergy History   *P*         
  --------------------------------------- ----------------- ----------- -------
  Demographics                                                          
   Age, mean (SD), y                      56.6 (15)         60.9 (18)   .05
   Male                                   169 (67)          34 (51)     .02
  Comorbidities                                                         
   Myocardial infarction                  56 (22)           24 (36)     .03
   Heart failure                          101 (40)          38 (58)     .01
   Vascular disease                       51 (20)           27 (41)     \<.01
   Cerebrovascular disease                80 (32)           34 (52)     \<.01
   Dementia                               9 (3)             2 (3)       .99
   Pulmonary                              90 (36)           27 (41)     .47
   Connective tissue disease              30 (12)           9 (14)      .68
   Peptic ulcer disease                   27 (11)           10 (15)     .38
   Liver disease                          25 (10)           5 (8)       .64
   Diabetes                               128 (51)          40 (60)     .17
   Diabetes with complications            71 (28)           24 (36)     .22
   Paraplegia                             15 (6)            2 (3)       .54
   Renal disease                          133 (53)          46 (69)     .02
   Cancer                                 77 (31)           12 (18)     .05
   Metastatic cancer                      39 (16)           4 (6)       .07
   Severe liver disease                   24 (10)           2 (3)       .13
   HIV                                    7 (3)             1 (2)       .99
  Charlson comorbidity index, mean (SD)   5.6 (3)           6.2 (3)     .23
  SOFA score, mean (SD)                   3.1 (3)           3.3 (3)     .58

Abbreviation: MSSA, methicillin-susceptible *Staphylococcus aureus*.

###### 

Site of Infection, Treatment, and Outcomes for 318 Patients With MSSA Bacteremia According to Penicillin Allergy

  Characteristics                    Allergy History   *P*        
  ---------------------------------- ----------------- ---------- --------
  Site of infection                                               
   Catheter                          41 (16)           5 (8)      .08
   Pneumonia                         18 (7)            4 (6)      .99
   Endovascular                      47 (19)           21 (32)    .03
   Osteoarticular                    43 (17)           11 (17)    .99
   Soft tissue                       50 (20)           21 (31)    .05
   Unknown                           63 (25)           14 (21)    .62
  Treatment                                                       
   Vancomycin                        28 (11)           25 (38)    \<.01
   Cefazolin                         98 (39)           29 (44)    .58
   Nafcillin                         113 (45)          3 (5)      \<.01
   Other                             13 (5)            9 (14)     .04
   Vancomycin trough, mean (SD)      16.1 (7)          16 (6)     .97
   Duration, mean (SD), wk           4.3 (2)           4.7 (2)    .25
   ID consultation                   146 (58)          49 (74)    .02
  Outcomes                                                        
   Time to clearance, mean (SD), d   4.1 (4)           6.2 (6)    \<0.01
   30-d mortality (%)                30 (11.9)         7 (10.6)   .99
   90-d mortality (%)                46 (18.3)         9 (13.6)   .47
   90-d recurrence (%)               4 (1.5)           5 (7.0)    .02

Abbreviation: MSSA, methicillin-susceptible *Staphylococcus aureus.*

When analyzed according to choice of definitive treatment, patients receiving vancomycin were more likely to have penicillin allergy, underlying diabetes, or renal disease, and they carried slightly higher mean SOFA scores (3.7 vs 2.9, *P* = .04) and Charlson comorbidity indices (6.6 vs 5.5, *P* = .03) ([Table 4](#T4){ref-type="table"}). Compared with patients treated with beta-lactam antibiotics, patients treated with vancomycin had higher mortality rates at 30 days (22.6% vs 7.4%, *P* = .002) and 90 days (26.4% vs 13.6%, *P* = .036) on univariate analysis. Patients who received beta-lactam antibiotics were more likely to have had an infectious diseases (ID) consultation than those receiving vancomycin, though the difference was not statistically significant (65% vs 53%, *P* = .12). Mortality rates were lower overall for patients receiving an ID consultation (8.7% vs 16.3% at 30 days, *P* = .04; 13.9% vs 22.8% at 90 days, *P* = .05). The initiation of mandatory ID consultation did not impact this finding (data not shown).

###### 

Demographics, Clinical Features, Site of Infection, and Outcomes for 296 Patients With MSSA Bacteremia Treated With Either Vancomycin or a Beta-Lactam

  Characteristics                    Definitive Antibiotic Choice   *P*          
  ---------------------------------- ------------------------------ ------------ -------
  Demographics                                                                   
   Age, mean (SD), y                 55.5 (17)                      58.0 (16)    .35
   Male                              31 (58)                        161 (66)     .34
   SOFA, mean (SD)                   3.7 (3.1)                      2.9 (2.5)    .04
   CCmI, mean (SD)                   6.6 (3)                        5.5 (3)      .03
   Penicillin allergic               25 (47)                        32 (13)      \<.01
  Site of infection                                                              
   Catheter                          9 (17)                         35 (14)      .67
   Pneumonia                         6 (11)                         15 (6)       .23
   Endovascular                      12 (23)                        53 (22)      .86
   Osteoarticular                    4 (8)                          49 (20)      .03
   Soft tissue                       11 (21)                        55 (23)      .86
   Unknown                           14 (26)                        53 (22)      .47
  Treatment                                                                      
   Vancomycin trough, mean (SD)      18.0 (6.1)                     15.3 (6.6)   .10
   Duration, mean (SD), wk           4.3 (1.8)                      4.5 (1.8)    .57
   ID consultation                   28 (53)                        159 (65)     .12
  Outcomes                                                                       
   Time to clearance, mean (SD), d   5.0 (5.3)                      4.4 (4.2)    .47
   30-d mortality (%)                12 (22.6)                      18 (7.4)     \<.01
   90-d mortality (%)                14 (26.4)                      33 (13.6)    .04
   90-d recurrence (%)               5 (9.4)                        3 (1.2)      \<.01

Abbreviation: CCmI, Charlson co-morbidity index; MSSA, methicillin-susceptible *Staphylococcus aureus*; SOFA, sequential organ failure assessment.

We next created a multivariable logistic regression model to quantify the effect of reported penicillin allergy on mortality outcomes while accounting for potential confounders. Our initial models included age \>65 years, sex, SOFA score, cancer, heart failure, kidney disease, skin/soft tissue source of infection, osteoarticular source of infection, penicillin allergy, and ID consultation. Both the 30- and 90-day models achieved c-statistics \>0.8. Severity of illness represented by the SOFA score was the strongest independent predictor of 30-day mortality in our adjusted model ([Table 5](#T5){ref-type="table"}). The following factors were independently associated with 90-day mortality in our adjusted model: age \>65 years, SOFA score, and congestive heart failure. Reported penicillin allergy had no significant effect on mortality at 30 or 90 days.

###### 

Logistic Regression Model to Quantify Effect of Penicillin Allergy on 30-Day and 90-Day Mortality Rates in Patients With MSSA Bacteremia While Adjusting for Confounders

  Variable               Odds Ratio (95% CI)   *P* Value
  ---------------------- --------------------- -----------
  30-d mortality model                         
   Penicillin allergy    0.73 (0.29--1.84)     .51
   SOFA score            1.32 (1.17--1.49)     \<.01
   Age \> 65 y           1.91 (0.91--3.98)     .09
  90-d mortality model                         
   Penicillin allergy    0.60 (0.15--1.40)     .23
   SOFA score            1.32 (1.17--1.48)     \<.01
   Age \> 65 y           1.94 (1.01--3.78)     .05
   CHF                   1.96 (1.03--3.75)     .04
   Cancer                2.28 (1.15--4.50)     .02

Abbreviations: CHF, congestive heart failure; CI, confidence interval; MSSA, methicillin-susceptible *Staphylococcus aureus*; SOFA, sequential organ failure assessment.

Considering that a significant proportion of patients with reported penicillin allergy still received cefazolin (44%, n = 29), we recreated the multivariable models to assess the effect of receiving a beta-lactam antibiotic on 30- and 90-day mortality ([Table 6](#T6){ref-type="table"}). Receipt of a beta-lactam was strongly protective against mortality at 30 and 90 days.

###### 

Logistic Regression Model to Quantify Effect of Beta-Lactam Receipt on 30-Day and 90-Day Mortality Rates in Patients With MSSA Bacteremia While Adjusting for Confounders

  Variable               Odds Ratio (95% CI)   *P* Value
  ---------------------- --------------------- -----------
  30-d mortality model                         
   Beta-lactam           0.26 (0.12--0.54)     \<.01
   SOFA score            1.30 (1.14--1.47)     \<.01
   Age \> 65 y           2.03 (0.96--4.30)     .06
  90-d mortality model                         
   Beta-lactam           0.41 (0.21--0.81)     .01
   SOFA score            1.30 (1.16--1.46)     \<.01
   Age \> 65 y           1.88 (0.97--3.64)     .06
   CHF                   1.94 (1.01--3.72)     .05
   Cancer                2.48 (1.26--4.90)     .01

Abbreviations: CHF, congestive heart failure; CI, confidence interval; MSSA, methicillin-susceptible *Staphylococcus aureus*; SOFA, sequential organ failure assessment.

Thirty-day mortality outcomes were stratified according to both penicillin allergy and definitive antibiotic choice in [Figure 1](#F1){ref-type="fig"}. No significant difference was noted in univariate analysis comparing mortality rates for penicillin-allergic or non-penicillin-allergic patients based on the definitive treatment received. We conducted additional analysis of these subgroups to test for possible interaction between reported penicillin allergy and receipt of a beta-lactam ([Table 7](#T7){ref-type="table"}). As predicted in our model, receipt of a beta-lactam was protective irrespective of penicillin allergy whereas vancomycin use was associated with higher rates of 30-day mortality. An interaction term was not significant in our final model but allowed us to calculate adjusted odds ratios for these subgroups. The single largest predictor of mortality was receipt of vancomycin among non-penicillin-allergic patients (odds ratio, 4.6; 95% confidence interval, 2.16--9.84; *P* \< .001 compared with the subgroup who received a beta-lactam and had no penicillin allergy).

###### 

Assessment for Interaction Between Penicillin Allergy and Receipt of a Beta-Lactam With Regards to 30-Day Mortality

  Subgroups                               Adjusted Odds Ratio (95% CI)   *P* Value
  --------------------------------------- ------------------------------ -----------
  Nonallergic, treated with beta-lactam   1.0                            NA
  Allergic, treated with beta-lactam      0.36 (0.09--1.41)              .09
  Nonallergic, treated with vancomycin    4.61 (2.16--9.84)              \<.01
  Allergic, treated with vancomycin       2.19 (0.88--5.46)              .14

Abbreviation: CI, confidence interval.

![Comparison of 30-day mortality rates for patients with methicillin-susceptible *Staphylococcus aureus* bacteremia according to penicillin allergy and definitive treatment. Note that some patients were treated with neither vancomycin nor a beta-lactam (eg, some received daptomycin, ceftaroline, linezolid and are not shown).](ofy04201){#F1}

Recognizing the known limitations of patient-reported drug allergy and the high prevalence of reported penicillin allergy (21%) in our cohort, we conducted a sensitivity analysis using a more stringent definition of penicillin allergy to assure against misclassification bias. According to the more stringent definition, only patients reporting anaphylaxis, hives, dyspnea, or angioedema/swelling were considered allergic. With the more stringent definition, incidence of penicillin allergy in our cohort fell to 9.2%---in agreement with previously reported prevalence rates \[[@CIT0005], [@CIT0006]\]. On sensitivity analysis, our modeled effect measures remained unchanged (data not shown).

We conducted a post hoc comparison between nafcillin and cefazolin given prior hypothetical concerns for inferior outcomes with cefazolin in deep-seated infections ([Table 8](#T8){ref-type="table"}) \[[@CIT0007], [@CIT0008]\]. Despite patients receiving cefazolin having higher SOFA scores (3.5 vs 2.2, *P* ≤ .01) and higher Charlson comorbidity indices (6.5 vs 4.5, *P* ≤ .01), we found no significant difference in 30-day (8.6% for nafcillin vs 6.3% for cefazolin, *P* = .63) or 90-day (12.9% vs 14.2%, *P* = .85) mortality rates. A higher incidence of renal disease in patients receiving cefazolin (65% vs 42%, *P* \< .01) may explain the trend toward higher SOFA and Charlson comorbidity indices, as renal failure is a component of both scores.

###### 

Demographics, Clinical Features, and Outcomes for 243 Patients With MSSA Bacteremia Receiving Either Cefazolin or Nafcillin

  Characteristics                 Definitive Antibiotic Choice   *P* Value   
  ------------------------------- ------------------------------ ----------- -------
  Demographics                                                               
   Age, mean (SD), y              59.3 (15)                      56.5 (16)   .18
   Male                           82 (65)                        79 (68)     .59
   SOFA, mean (SD)                3.5 (2.6)                      2.2 (2.3)   \<.01
   CCmI, mean (SD)                6.5 (3)                        4.5 (3)     \<.01
  Site of infection                                                          
   Catheter                       24 (19)                        11 (10)     .04
   Pneumonia                      9 (7)                          6 (5)       .60
   Endovascular                   34 (27)                        19 (16)     .06
   Osteoarticular                 21 (17)                        28 (24)     .15
   Soft tissue                    24 (19)                        31 (27)     .17
   Unknown                        25 (20)                        28 (24)     .44
  Outcomes                                                                   
   Time to clearance, mean (SD)   4.5 (5)                        4.2 (3)     .55
   30-d mortality (%)             8 (6.3)                        10 (8.6)    .63
   90-d mortality (%)             18 (14.2)                      15 (12.9)   .85

Abbreviations: CCmI, Charlson co-morbidity index; SOFA, sequential organ failure assessment.

DISCUSSION {#s7}
==========

While prior studies have assessed the effects of different antibiotics on outcomes in MSSA bacteremia, few have examined the effect of reported penicillin allergy \[[@CIT0007]\]. In this retrospective cohort study, reported penicillin allergy did not significantly impact 30- or 90-day mortality rates. While the overall prevalence of reported penicillin allergy was higher than previously reported, many of these reactions were either undocumented or involved a nonspecific rash. Nearly half of penicillin-allergic patients were still safely treated with cefazolin---consistent with either over-reporting of allergy or the low incidence rate for cross-reactivity with cefazolin in particular \[[@CIT0008]\]. Patients receiving beta-lactams consistently had the lowest mortality rates (7.4%), regardless of reported allergy history, even after we applied a more stringent allergy definition. This suggests that reported penicillin allergy was not an accurate marker for clinically relevant reactions concerning enough to avoid cephalosporins. The most striking mortality gap is the 4-fold greater mortality rate for nonallergic patients receiving vancomycin instead of a beta-lactam. Multivariable modeling also confirmed receipt of a beta-lactam as the single strongest predictor of survival, regardless of reported allergy history or adjustment for more stringent criteria defining penicillin allergy. These data highlight 2 crucial points for improving outcomes in MSSA bacteremia. First, a reported penicillin allergy only matters if it prevents a patient from receiving a beta-lactam. Second, while clearly over-reported, penicillin allergy is not the only reason that patients are missing out on optimal therapy.

The superiority of beta-lactams over vancomycin in treating MSSA bacteremia is consistent with several prior studies \[[@CIT0009]\]. In our study, vancomycin use was associated with a 3-fold higher mortality rate at 30 days (*P* = .002) and a 2-fold higher mortality rate at 90 days (*P* = .036). Others have separately examined the influence of reported penicillin allergy on treatment choice---concluding that penicillin allergy was associated with an increased likelihood of receiving vancomycin by nearly 3-fold, in close agreement with the 3.3-fold increase we found \[[@CIT0007]\].

With such a stark difference in mortality rates, and clear evidence that patients with a reported penicillin allergy can still achieve superior outcomes if they receive another beta-lactam, our data suggest that every effort should be made to ensure that patients with MSSA bacteremia receive a beta-lactam. These efforts take several forms. Simple interventions such as an enhanced drug allergy history may reveal that patients can safely tolerate cephalosporins, as was the case for 44% of our penicillin-allergic cohort. In prior studies of patients with reported allergies, nearly 50% of patients could be transitioned to a beta-lactam based on more detailed drug history alone \[[@CIT0020], [@CIT0021]\]. When uncertainty persists, penicillin skin testing can be used to determine whether penicillin antibiotics can be given safely \[[@CIT0022]\]. Formal testing confirms 5% or less of reported penicillin allergies---permitting still more patients to receive preferred therapy \[[@CIT0005]\]. While all of these interventions are being actively applied and studied presently (including at our own institution), the question of how to manage the remaining patients with true penicillin allergy remains. A 2- to 3-fold increase in mortality seems unacceptable for second-line therapy of a treatable disease (in this case, use of vancomycin). It may be time to consider desensitization as a preferred next step in the management of MSSA bacteremia for the truly allergic patients. Certainly the precedent exists when other medications are felt to be crucial to outcomes (eg, penicillin desensitization for neuro-syphilis or aspirin desensitization for coronary artery disease). As far as we are aware, no studies have examined this strategy to date.

Until desensitization can be fully evaluated as a treatment for MSSA bacteremia in penicillin-allergic patients, cefazolin often becomes the default beta-lactam in the subset of patients allergic to penicillin but tolerant of cephalosporins. The use of cefazolin carries with it some concerns based on a few case reports describing treatment failures, particularly in deep-seated MSSA infections, theoretically attributed to an inoculum effect \[[@CIT0029], [@CIT0030]\]. To add to the body of evidence addressing these concerns, we also conducted a post hoc subanalysis comparing outcomes between nafcillin and cefazolin and found no significant difference in 30- or 90-day mortality rates, despite patients receiving cefazolin having higher mean SOFA and Charlson comorbidity scores. Cefazolin's ability to achieve similar outcomes despite predictors usually associated with higher mortality is both reassuring and consistent with prior evidence \[[@CIT0013], [@CIT0014]\]. Indeed, the recently published literature suggests that outcomes with cefazolin are comparable to outcomes with nafcillin but with fewer adverse effects \[[@CIT0031]\].

Outside of the issues surrounding treatment of penicillin-allergic patients, the remaining nonallergic patients who received vancomycin (nearly 10% in our study) pose a distinct challenge worthy of further study as well. Vancomycin might be chosen for a variety of other reasons---including persistent knowledge gaps among providers regarding vancomycin's efficacy in MSSA bacteremia, concern for alternate sources of infection or other pathogens, or the impression of convenient dosing (eg, infrequent dosing or dosing with dialysis). Investigating the reasons for vancomycin use other than true drug allergy might help target quality improvement or antimicrobial stewardship efforts and prevent the use of a less efficacious drug in this population as well.

Our study carries several limitations. First, penicillin allergy was determined based on documentation in the history and physical, which has known problems with measurement error \[[@CIT0032], [@CIT0033]\]. While the prevalence of penicillin allergy was high, a significant proportion of reactions were either unspecified or nonspecific---consistent with likely over-reporting of penicillin allergy. We conducted a sensitivity analysis using a more stringent allergy definition to assess for misclassification bias, with no alteration in any of our primary effect measures. Irrespective of accuracy, reported drug allergy remains clinically relevant given that treatment decisions are typically made based on the treating physician's assessment. Second, we did not have sufficient numbers to adequately assess adverse drug events. Third, any comparisons with vancomycin must be considered with the caveat that vancomycin troughs were not available for many patients, particularly after discharge, and thus we are unable to assure therapeutic levels for the duration of treatment. Finally, given the diversity of infections included, we were unable to include an assessment of source control as another factor potentially influencing mortality. We hope to incorporate these additional factors in our ongoing and future research.

In summary, reported penicillin drug allergy did not equate with increased mortality in MSSA bacteremia in our cohort. We believe this is because nearly half of the labeled "allergic" group still received a beta-lactam. Receipt of a beta-lactam, including the use of cefazolin in many patients with reported penicillin allergy, was the single strongest predictor of survival. Conversely, patients receiving vancomycin---whether due to a drug allergy history or other reasons---suffered 2- to 3-fold higher mortality rates. In particular, patients who received vancomycin without a drug allergy had the highest mortality risk. Further investigation is needed to understand why some nonallergic patients still receive vancomycin. These data highlight 2 crucial points for improving outcomes in MSSA bacteremia. First, penicillin allergy only matters if it prevents a patient from receiving a beta-lactam. Second, penicillin allergy is not the only reason that patients are missing out on optimal therapy. Future efforts should include improvement of allergy assessment and documentation, de-labeling patients based on reactions unconcerning for true allergy, and perhaps even desensitization for truly penicillin-allergic patients.
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